Dr Grace C. Wright Envisions Role of Vectra DA in Future RA Guidelines

As more organizations begin to issue guidelines for the treatment of rheumatoid arthritis, they will incorporate recommendations to determine whether a drug is working. One option that can help give effective care and streamline patient managements is the use of the Vectra DA test, explained Grace C. Wright, MD, PhD, clinical associate professor of medicine and attending rheumatologist at New York University Langone Medical Center.

Transcript (slightly modified)

Do you think we will see more professional organizations join United Rheumatology in including Vectra DA in guidelines?

It is our hope that we’ll have many such pathways by other organizations, because it really helps to streamline the management of patients, and certainly that is my hope.

Why do you think a test like Vectra DA hasn’t been added to any other guidelines yet?

A lot of organizations are forming now and just creating guidelines for the first time. We have the [American College of Rheumatology] guidelines that really give us this global management, but regionally a lot of groups are starting to find ways to give effective, cost-effective care. And so incorporating personal guidelines, so that physicians can really sort of target how they treat to specific targets and not spend 6 or 9 months on a drug that’s not working. Guidelines are really something that we’re seeing much more commonly created now.